^
    No biomarker
    Pancreatic Adenocarcinoma
    gemcitabine + albumin-bound paclitaxel
    Sensitive
    :
    A1
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan
    Sensitive
    :
    A1
    No biomarker
    Pancreatic Adenocarcinoma
    LV5FU2
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    CAPOX
    Sensitive
    :
    A2
    NTRK3 fusion
    Pancreatic Adenocarcinoma
    larotrectinib
    Sensitive
    :
    A2
    NTRK2 fusion
    Pancreatic Adenocarcinoma
    larotrectinib
    Sensitive
    :
    A2
    NTRK3 fusion
    Pancreatic Adenocarcinoma
    entrectinib
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    erlotinib
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    capecitabine
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil + capecitabine
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    gemcitabine + capecitabine
    Sensitive
    :
    A2
    BRCA1 mutation
    Pancreatic Adenocarcinoma
    cisplatin + gemcitabine
    Sensitive
    :
    A2
    BRCA2 mutation
    Pancreatic Adenocarcinoma
    cisplatin + gemcitabine
    Sensitive
    :
    A2
    PALB2 mutation
    Pancreatic Adenocarcinoma
    cisplatin + gemcitabine
    Sensitive
    :
    A2
    No biomarker
    Pancreatic Adenocarcinoma
    5-fluorouracil + irinotecan
    Sensitive
    :
    A2
    NTRK1 fusion
    Pancreatic Adenocarcinoma
    entrectinib
    Sensitive
    :
    A2
    MSI-H/dMMR
    Pancreatic Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    A2
    NTRK2 fusion
    Pancreatic Adenocarcinoma
    entrectinib
    Sensitive
    :
    A2
    NTRK1 fusion
    Pancreatic Adenocarcinoma
    larotrectinib
    Sensitive
    :
    C1
    RET fusion
    Pancreatic Adenocarcinoma
    pralsetinib
    Sensitive
    :
    C1
    TMB-H
    Pancreatic Adenocarcinoma
    pembrolizumab
    Sensitive
    :
    C1
    KRAS G12R
    Pancreatic Adenocarcinoma
    selumetinib
    Sensitive
    :
    C3
    VERI is free for non-commercial use, no login needed.
    Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
    For commercial access, including additional premium features, please contact us.
    By using VERI, you are agreeing to our
    and
    Privacy Policy
    ACCEPT COOKIES